Navigation Links
TheraQuest's IND for Abuse Deterrent Strong Opioid (TQ-1015) Accepted by FDA
Date:11/12/2008

BLUE BELL, Pa., Nov. 13 /PRNewswire/ -- TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using SECUREL(R), TheraQuest's proprietary abuse deterrent technology.

Najib Babul, PharmD, Chief Executive Officer of TheraQuest stated, "Sustained release opioids are the standard of care for the management of chronic pain. Unfortunately, it is easy to defeat the sustained release mechanim of such dosage forms, making them subject to drug diversion and drug abuse. The TQ-1015 dosage form is highly tamper resistant, when compared to OxyContin(R), thereby minimizing abuse by recreational drug users and drug addicts."

About TQ-1015

TQ-1015 is a once-a-day extended release opioid analgesic for the treatment of chronic pain. It has been developed using TheraQuest's proprietary abuse deterrent extended release drug delivery system (SECUREL(R)). TQ-1015 is significantly more potent than many current oral therapies, including morphine and oxycodone. It shows robust efficacy in various animal models of acute pain, inflammatory pain and neuropathic pain. TQ-1015 will compete in the $8.3 billion U.S. opioid market.

About SECUREL(R)

Recent experience with extended release opioid pain relievers has shown that intentional crushing or extraction of the active ingredient from the dosage form by addicts and recreational drug users can destroy the timed-release mechanism and result in a rapid surge of drug into the bloodstream. Serious side-effects and death have been reported from such misuse.

SECUREL(R) is TheraQuest's proprietary abuse deterrent extended release technology for oral abusable drugs. SECUREL(R) dosage forms cannot be easily crushed for inhalation or to obtain rapid euphoria from high blood levels when swallowed. It is also exceedingly difficult for I.V. abusers to extract the active drug from the dosage form using common solvents, including alcohol.

About TheraQuest

TheraQuest Biosciences, Inc. (http://www.theraquestinc.com) is a private, development-stage pain management company building a diversified portfolio of pharmaceutical products to address a critical area of unmet medical need. Despite their limitations, current treatments for acute and chronic pain yield worldwide sales in excess of $30 billion. The TheraQuest team has contributed to the development of numerous analgesics approved in the U.S. over the past 20 years. TheraQuest's strategy is to use its expertise to identify, develop and commercialize product candidates with strong market potential that have lower development costs and reduced regulatory risk than new chemical entities. TheraQuest is headquartered in Blue Bell, Pennsylvania.

TheraQuest is funded in part by BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania and Ben Franklin Technology Partners of Southeastern Pennsylvania.

SECUREL(R) and OxyContin(R) are registered trademarks of TheraQuest Biosciences, Inc., and Purdue Pharma LP., respectively.


'/>"/>
SOURCE TheraQuest Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Disability payments may spur drug abuse
2. Leading Child Abuse Center Releases Back to School Tips to Protect Children From Internet Predators
3. Inhalant Abuse Prevention Program to Be Launched in Maryland Schools
4. Research examines connection between substance abuse and violence
5. Steroids Are Abused for Skin, Not Just Muscles
6. L.A. Author, TV Personality and Substance Abuse Specialist Discusses Struggle to Break Bad-girl Syndrome Oct. 26-28 in Baltimore
7. Dealing with stress as a treatment for alcohol abuse
8. Culture can Affect Access to Alcohol, Drug Abuse Treatment for Rural Youth
9. King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion(R) (Abuse-Deterrent) Technology
10. CHPA Commends Senator Biden on Legislation Aimed at Curbing Medicine-Abuse Trend
11. Substance abuse practitioners ask what is recovery?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 2016 , ... In an article published April 16th on the ... and lip injections, which she underwent in order to feel more at home at ... Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic surgeons ...
(Date:4/29/2016)... Newport Beach, Calif. (PRWEB) , ... April 29, 2016 , ... ... affect us. An effective way to confront and deal with these stressors is to ... taste bad to be good for you. Risa Groux, a certified Holistic Nutritionist and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House announced ... loans, more information about their loan terms and accounts, and more protections for ... including federal and private loans, has reached $1.3 trillion, with 43 million Americans ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine physician ... one of their physicians has been invited to be a featured speaker at the ... Review conference on April 30, 2016. , Dr. R. Scott McPherson, a physical ...
(Date:4/29/2016)... ON (PRWEB) , ... April 29, 2016 , ... ... and the Canadian Celiac Association (CCA), is pleased to announce the launch of ... gluten-free products, nutritional articles, recipes, and more. The purpose of the GFCP ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/27/2016)... Mass., April 27, 2016  Hologic, Inc. (Nasdaq: ... financial results for the fiscal second quarter ended ... (EPS) of $0.24 increased 41.2%, and non-GAAP diluted ... million increased 5.8% on a reported basis, and ... "We posted another good quarter, highlighted by ...
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
Breaking Medicine Technology: